sorry, we can't preview this file

...but you can still download Supplementary Figures.docx

Supplementary Figures.docx (1.48 MB)

Supplementary Figures – Efficacy and Safety of First-Line Therapies in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis

figure

posted on 2022-02-21, 12:36 authored by Figshare Future Science GroupFigshare Future Science Group, Katrin Haeussler, Xuan Wang, Katherine B Winfree, Yulia D'yachkova, Sory Traore, Tarun Puri, Howard Thom, Christos Papagiannopoulos, Maria Nassim, Kaisa Taipale

Figure A1. Sensitivity analysis of PFS splitting the erlotinib and gefitinib node (random effects).

Figure A2. Subgroup analysis of PFS of treatments versus erlotinib/gefitinib in East Asian patients (random effects).

Figure A3. Subgroup analysis of PFS of treatments versus erlotinib/gefitinib in non-East Asian patients (random effects).

Figure A4. Subgroup analysis of PFS of treatments versus erlotinib/gefitinib in exon 19 deletion patients (random effects).

Figure A5. Subgroup analysis of PFS of treatments versus against erlotinib/gefitinib in patients with L858 mutations (random effects).

Figure A6. Subgroup analysis of PFS of treatments versus erlotinib/gefitinib excluding brain metastasis (random effects).

Figure A7. Sensitivity analysis of OS splitting the erlotinib and gefitinib node (random effects).

Figure A8. Subgroup analysis of OS of treatments versus erlotinib/gefitinib excluding brain metastasis (random effects).

Figure A9. Evidence network for sensitivity analysis splitting ERL and GEF nodes for PFS

Figure A10. Evidence network for sensitivity analysis splitting ERL and GEF nodes for OS

Funding

Eli Lilly & Co.,IN, USA

History

Usage metrics

Future Oncology

Keywords

EGFR positive network meta-analysis systematic literature review non-small-cell lung cancer progression-free survival tyrosine kinase inhibitors Cancer Therapy (excl. Chemotherapy and Radiation Therapy)Solid Tumours

Licence

CC BY-NC-ND 4.0